Neurocrine Biosciences (NBIX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $1.39
- EPS estimate
- $1.66
- EPS surprise
- −16.38%
- Revenue surprise
- +7.61%
- Revenue
- $959.0M
- Revenue estimate
- $891.2M
- Reported
- Jul 30, 2026
Neurocrine Biosciences reported Q2 2026 results on July 30, 2026. Earnings per share were $1.39, below the $1.66 estimate by 16.38%. Revenue was $959.0 million, ahead of the $891.2 million consensus by 7.61% and the highest quarter in the table. Compared with Q2 2025, EPS rose about 31% from $1.06 and revenue rose about 39% from $687.5 million.
Growth has been steady on an annual basis. EPS rose from $1.53 in 2022 to $2.42 in 2023, $3.29 in 2024 and $4.66 in 2025, while revenue climbed each year from $1.49 billion to $2.86 billion. Quarterly EPS is far less even. Neurocrine posted losses in Q4 2021, Q2 2022 and Q1 2023, and the high in the table is $2.04 in Q3 2025. The first half of 2026 adds up to $3.30 per share, compared with $1.14 in the first half of 2025. EPS beat the estimate in only 5 of the last 20 quarters.
Neurocrine reported Q3 between October 28 and November 1 in each of the past five years. That points to late October or early November 2026 for the next report, which will show whether revenue keeps its year-over-year growth.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $1.66 | $1.39 | −16.38% | $959.0M | SEC |
| Q1 2026 | May 5, 2026 | $1.22 | $1.91 | +57.05% | $814.5M | SEC |
| Q4 2025 | Feb 11, 2026 | $1.80 | $1.48 | −17.97% | $805.5M | SEC |
| Q3 2025 | Oct 28, 2025 | $1.59 | $2.04 | +27.95% | $794.9M | SEC |
| Q2 2025 | Jul 30, 2025 | $0.96 | $1.06 | +9.89% | $687.5M | SEC |
| Q1 2025 | May 5, 2025 | $0.54 | $0.08 | −85.05% | $572.6M | SEC |
| Q4 2024 | Feb 6, 2025 | $1.61 | $1.00 | −37.73% | $627.7M | SEC |
| Q3 2024 | Oct 30, 2024 | $1.49 | $1.24 | −16.92% | $622.1M | SEC |
| Q2 2024 | Aug 1, 2024 | $1.13 | $0.63 | −44.16% | $590.2M | SEC |
| Q1 2024 | May 1, 2024 | $1.10 | $0.42 | −61.75% | $515.3M | SEC |
| Q4 2023 | Feb 7, 2024 | $1.21 | $1.44 | +18.81% | $515.2M | SEC |
| Q3 2023 | Oct 31, 2023 | $1.04 | $0.82 | −21.11% | $498.8M | SEC |
| Q2 2023 | Aug 1, 2023 | $0.81 | $0.95 | +16.62% | $452.7M | SEC |
| Q1 2023 | May 3, 2023 | $0.62 | −$0.79 | −228.06% | $420.4M | SEC |
| Q4 2022 | Feb 6, 2023 | $1.12 | $0.88 | −21.42% | $412.0M | SEC |
| Q3 2022 | Nov 1, 2022 | $0.81 | $0.69 | −14.76% | $387.9M | SEC |
| Q2 2022 | Aug 4, 2022 | $0.61 | −$0.18 | −129.57% | $378.2M | SEC |
| Q1 2022 | May 4, 2022 | $0.35 | $0.14 | −59.63% | $310.6M | SEC |
| Q4 2021 | Feb 11, 2022 | $0.68 | −$0.08 | −111.81% | $312.0M | SEC |
| Q3 2021 | Nov 1, 2021 | $0.56 | $0.23 | −58.69% | $296.0M | SEC |
Quarterly revenue
Frequently asked questions
When did Neurocrine Biosciences (NBIX) last report earnings?
Neurocrine Biosciences last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did NBIX beat earnings estimates?
No. Neurocrine Biosciences reported EPS of $1.39 for Q2 2026 against a $1.66 estimate — a 16.38% miss.
How much revenue did NBIX report last quarter?
Neurocrine Biosciences reported $959.0M in revenue for Q2 2026, against a consensus estimate of $891.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.